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Abstract
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome affects at least 1 out of 4500 women and
has for a long time been considered as a sporadic anomaly. Congenital absence of upper vagina and
uterus is the prime feature of the disease which, in addition, is often found associated with unilateral
renal agenesis or adysplasia as well as skeletal malformations (MURCS association). The phenotypic
manifestations of MRKH overlap various other syndromes or associations and thus require
accurate delineation. Since MRKH manifests itself in males, the term GRES syndrome (Genital,
Renal, Ear, Skeletal) might be more appropriate when applied to both sexes. The MRKH syndrome,
when described in familial aggregates, seems to be transmitted as an autosomal dominant trait with
an incomplete degree of penetrance and variable expressivity. This suggests the involvement of
either mutations in a major developmental gene or a limited chromosomal deletion. Until recently
progress in understanding the genetics of MRKH syndrome has been slow, however, now HOX
genes have been shown to play key roles in body patterning and organogenesis, and in particular
during genital tract development. Expression and/or function defects of one or several HOX genes
may account for this syndrome.
Introduction
Müllerian and Wolffian ducts are the primordia for the
internal reproductive systems of females and males
respectively and co-exist in the undifferentiated embryo
until genetic sex triggers differentiation of either ovaries or
testes. Müllerian ducts differentiate into Fallopian tubes,
uterus, cervix and upper part of the vagina while the Wolf-
fian ducts degenerate. In the male testicular production of
anti-Müllerian hormone (AMH) and androgens leads to
the development of the Wolffian ducts into vas deferens
and seminal vesicles.
Various forms of Müllerian abnormalities range from
minor anatomical variations up to total aplasia, the latter
being diagnosed as Mayer-Rokitansky-Küster-Hauser
(MRKH) syndrome in 90% of affected women. The fre-
quency of congenital absence of vagina and uterus is not
yet entirely clear, although reported incidences vary from
1 in 4,000 to 5,000 female births [1,3]. In women present-
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ing with primary amenorrhea, MRKH is fairly common,
being second to gonadal dysgenesis as a cause of amenor-
rhea [4,5]. Although the vast majority of cases of MRKH
seem to be sporadic [5] familial aggregates have been
reported [1,6,8].
Women with Müllerian agenesis show normal 46, XX
karyotypes [9-12], normal external genitalia and func-
tional ovaries [13,14], there are however cases of poly-
cystic ovaries [15,16] and ovarian tumors [17-20].
Examination reveals an absence or severe hypoplasia of
the upper vagina as well as frequent uterine agenesis. Due
to a different embryonic origin, the lower third of the
vagina is always present, [21,22]. There appears to be two
subtypes of MRKH: the typical (also called type I or iso-
lated) and the atypical form (type II): the frequency of
type II being much greater [23]. The typical form is char-
acterized by laparoscopic or laparotomic findings of sym-
metric muscular buds (the Müllerian remnants) and
normal Fallopian tubes; this is referred to as the so-called
Rokitansky sequence, where only the caudal part of the
Müllerian duct (upper vagina and uterus) is affected [24]
(OMIM 277000 [25]). The atypical form shows, in addi-
tion, asymmetric hypoplasia of one or two buds, with or
without dysplasia of the Fallopian tubes: this is often asso-
ciated with other anomalies, including mainly renal
defects (unilateral agenesis or ectopia of one or both kid-
neys, horseshoe kidney, in about 40–60% of patients)
[26], cervico-thoracic (asymmetric, fused or wedged verte-
brae, scoliosis and Klippel-Feil anomaly in about 20% of
patients) [26] and, to a minor extend, hearing defects
[27,28] and digital anomalies of varying severities
[1,10,29-33]. For these reasons, clinicians use the term
MURCS (MÜllerian Renal Cervical Somite) association
[12,34] which is the most severe form of the disorder
(OMIM 148860 and 601076 [25]). It may be attributed to
an alteration of the blastema of the cervicothoracic
somites and the pronephric ducts which, by the end of the
fourth week of fetal life, have an ultimately spatial rela-
tionship [12]. These overall features clearly differentiate
Table 1: Genetic diseases featured by Müllerian, renal and skeletal malformations: similarities and differences with MRKH syndrome/
MURCS association.
MRKH/MURCS Klippel-Feil VATER FAV spectrum Winter synd. HRA
OMIM 277000/601076 OMIM 148860 OMIM 192350 OMIM 164210 OMIM 267400 OMIM 191830
uterus aplasia uterus aplasia uterus aplasia uterus malform.
vaginal aplasia vag. aplasia atresia (1) vaginal aplasia vaginal atresia (1) vaginal malform.
kidney malform. (2) kidney malform. (2) kidney malform. (2) kidney malform. (2) renal agenesis (3) renal agenesis (3)
short neck short/web neck
scoliosis scoliosis
other vert. defects other vert. defects other vert. defects other vert. defects
rib defects rib defects rib defects
thumb hypoplasia thumb hypoplasia thumb hypoplasia
radius hypoplasia
polydactyly
deafness deafness deafness deafness
malf. ext. ears malf. ext. ears malf. ext. ears
low set ears
facial asymmetry facial asymmetry facial asymmetry
malar hypoplasia
maxilary hypoplas.
micrognathia micrognathia
macrostomia
strabismus
microphtalmos
iris coloboma
glaucoma
cleft lip/palate cleft palate w/o lip cleft lip/palate
cleft tongue
single ombilic artery
anal atresia
trach-oesoph. fistula
cardiac defects cardiac defects cardiac defects cardiac defects
Frequency of malformations is indicated as follow: very frequent occasional rarely observed
(1): vaginal atresia affects the lower part of the vagina and is far different from vaginal aplasia found in MRKH/MURCS and which affects the upper 
(~2/3) part of the vagina.
(2): kidney malformations include unilateral agenesis, ectopia of one or both kidneys, horseshoe kidney. Bilateral agenesis can be found post mortem.
(3): unilateral or bilateral renal agenesis.Journal of Negative Results in BioMedicine 2006, 5:1 http://www.jnrbm.com/content/5/1/1
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the MRKH syndrome from other defects of genital tract
development such as androgen peripheral insensitivity
(patients 46, XY) [6,35] or Turner's syndrome (patients
45, X) [36].
Treatment
Treatment is usually delayed until the patient is ready to
start sexual activity. It may be either surgical or non-surgi-
cal but the chosen method needs to be tailored to the indi-
vidual needs and motivation of the patient and the
options available [37]. For instance the Vecchietti opera-
tion is a mixture of surgical and non-surgical methods of
creating a neovagina and has been performed frequently
in Europe over the last 20 years [38].
In addition, it is important to manage psychological
symptoms in women with Müllerian agenesis. Indeed a
young woman who discovers that she has a congenital
malformation involving her reproductive organs may
develop extreme anxiety about her feminity and physical
image. The psychological adjustment and general attitude
are therefore also very important in deciding what proce-
dure should be used and when [39].
Similarities of MURCS association with other syndromes 
(Table 1)
Although utero-vaginal aplasia should be the obligatory
start point in establishing MRKH syndrome, associated
malformations (see introduction) may be misleading and
steer clinicians towards a false diagnosis. On the other
hand, finding of Müllerian abnormalities in a patient
showing features of an other predominant syndrome can
also be confusing. Therefore, the use of the general term
"Müllerian abnormalities/anomalies" should be banished
as it refers to variable malformations ranging from minor
anatomical variations up to total aplasia [21,30]. In addi-
tion, accurate delineation of associated malformations
may be a great help in establishing a MRKH syndrome
[22].
Indeed, most of the defects that form parts of the MURCS
association [12] can be observed optionally and in vari-
ous combinations as do those described in the VATER
association (Vertebral defects, Anal atresia, Tra-
cheoEsophageal fistula and/or oesophageal atresia, Radial
dysplasia, Renal defects) [40,42], both syndromes sharing
in common several of these defects, mainly renal, verte-
bral and upper limb but being distinct clinical entities
[12,30,43]. Although frequency of renal defects is about
the same in both syndromes [1,44], utero-vaginal dyspla-
sia, the prime feature of the MURCS association, is how-
ever a rare trait of VATER patients. Finally, discrepancy can
be made upon features not found in the MURCS but fre-
quent in VATER, such as T-E fistula with oesophageal
atresia (70%) and anal atresia (80%) [43,45].
Another source of confusion is that of the Winter syn-
drome [46], commonly described in the literature as a
"syndrome of renal, genital and middle ears anomalies"
[46-49]. Patients are initially found to have bilateral sten-
osis of the external auditory canals in their youth but diag-
nosis is made only after primary amenorrhoea has led to
vaginal atresia and unilateral renal agenesis being
revealed after further examination [49]. In the reports
cited above, the genital anomalies are however restricted
to a distal vaginal atresia which is far different from the
Müllerian aplasia observed in the MRKH syndrome, even
in its mildest form, where only the upper vagina is absent.
Moreover, while partial or total Müllerian aplasia confers
irreversible sterility, vaginal atresia can be surgically cor-
rected to permit pregnancy [49].
MRKH has also been described in association with other
syndromes, especially hereditary renal adysplasia (HRA)
[50,53] and facio-auriculo-vertebral (Goldenhar) spec-
trum (FAVS) [54,58] in women otherwise presenting nor-
mal karyotypes and normal female secondary sex
characteristics. In HRA, where uni- and bi-lateral renal
agenesis (URA and BRA) can be observed in the same fam-
ily, Müllerian anomalies are rarely encountered and
appear to be an occasional secondary manifestation of the
syndrome. They consist in minor abnormalities such as
didelphic uterus [50] or unicornate uterus [51] that can
often be surgically corrected to permit pregnancy. Finally,
none of the other malformations that form part of the
MURCS association, such as vertebral or auditory defects,
is ever found in HRA [50,53]. Investigation of family his-
tory, when available, should then allow a distinction to be
made, according to whether URA and/or BRA is the only
malformation seen in the family (familial HRA) or if
other anomalies specific to MRKH, such as vertebral or
isolated Müllerian aplasia are evidenced.
Concurrence of MURCS and FAVS is puzzling. Indeed
some reports on MURCS include all combinations of ear,
vertebral and facial defects that are the main features of
FAVS. This consequently leads to question whether
MURCS and FAVS are two separate entities or various
manifestations of the same syndrome/association. Most
of the reports are in favour of independent malformative
associations as the vast majority of each MURCS or FAVS
occurs without any feature of the other (see Table 1).
Genetics of the MRKH syndrome
Although the pathogenesis of Müllerian aplasia with or
without associated malformations is now well described,
its etiology remains unknown [59] and therefore, its
familial occurrence is of considerable interest. The appar-
ent lack of familial transmission initially suggested the
involvement of non-genetic factors [21] such as thalido-
mide-like teratogens [12,60] however pregnancy histories,Journal of Negative Results in BioMedicine 2006, 5:1 http://www.jnrbm.com/content/5/1/1
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when available, have never revealed any association with
any record of drug use, illness, or exposure to known ter-
atogens.
In almost all reports, karyotypes of patients are that of
normal 46, XX women. Rare chromosome abnormalities
have been found associated with Müllerian aplasia, such
as mosaicisms [61,62], rearrangements/deletions [11],
often associated with gonadal dysgenesis [63,65], or both
[66]. It is noteworthy that, in these rare cases, only the X
chromosome seems to be involved and therefore appears
to carry a gene(s) involved in early differentiation of at
least both gonads and Müllerian ducts.
Most reports of Müllerian dysplasia/aplasia have focused
on patients' defects and their surgical treatment, without
reporting family histories. This may explain why the
majority of cases have been assumed to be sporadic. How-
ever, reference work of Griffin and co-workers [1] showed
significant incidence (>20%) of familial cases: they
described a triad of main features of MRKH – Müllerian
aplasia, spine and kidney involvement, these two latter
being optionally observed in combination with the first
and interestingly, occurring in more distant relatives as
well as mothers. This has been confirmed by other reports
[7,53,67] and raised the question of whether or not the
MRKH was manifested in the male. In fact combinations
of Wolffian duct agenesis or severe hypoplasia, with or
without renal and/or skeletal anomalies have been
described, as both congenital unilateral renal agenesis
associated with ipsilateral agenesis of the vas deferens
[68,69], and as primary infertility due to azoospermia
associated with Klippel-Feil deformity [70] or segmenta-
tion abnormalities of the cervico-thoracic spine and hear-
ing impairment [71,72]. In azoospermic patients, the
infertility seems to be attributable to uni- or bi-lateral
defect of vas deferens development ranging from hypopla-
sia [70] to agenesis [69,72,73], leading to so-called
obstructive azoospermia. Given that the acronym MURCS
cannot apply to males, it has been suggested that the male
counterpart ARCS (Azoospermia, Renal anomalies, Cervi-
cothoracic Spine dysplasia) would be more suitable to
designate this condition [71,72] although GRES (Genital
Renal Ear Skeletal) which applies to both sexes [23] would
be even more appropriate. As therefore expected, cases
exist where both MURCS and ARCS have been found in
the same family [73].
From the data cited above, it seems that Müllerian aplasia
can represent only one manifestation of a variably
expressed genetic defect, and since the detection and defi-
nition of the features of MRKH have an element of unreli-
ability, it is likely that the real frequency of familial
occurrence has been underestimated. Furthermore, a con-
tribution to the genetic disorder can clearly be transmitted
by either father or mother, neither of whom may express
any of the defects or at least those which are not deleteri-
ous for reproduction (for example unilateral renal agene-
sis, skeletal anomalies or deafness). Consequently,
although these overall data are broadly compatible with a
classic model of multifactorial/polygenic inheritance, as
often suggested [5,8,21,74,75], it seems that a more likely
mode of transmission is that of an autosomal dominant
trait with an incomplete degree of penetrance coupled
with a highly variable expressivity of a single mutant gene
as previously hypothesized [1,53,73] or of a limited dele-
tion undetectable in standard karyotypes.
Candidate gene approaches
Up to now, the lack of families with informative genetic
histories has not allowed the identification of any locus by
standard genetic linkage analysis. An alternative approach
based either on an apparent association with other genetic
diseases or on pleiotropic action during embryogenesis
and consequent manifestations as developmental field
defects, has led to several genes investigation. Genetic
association of MRKH with galactosemia [76] or with cystic
fibrosis [4] has been analysed but neither the gene for
galactose-1-phosphate uridyl transferase (GALT) [77] nor
the gene encoding the CFTR chloride channel [4] showed
any mutation and/or polymorphism associated with
Müllerian aplasia. Genes acting during early development
such as WT1 and PAX2 have also been suggested as candi-
dates, although so far with no demonstration of their role
in MRKH syndrome [78,79]. Moreover, anti-Müllerian
hormone or its receptor, together responsible for Mülle-
rian duct regression in male fetuses [80] and therefore
good candidates, have no etiological role in the syndrome
[81]. It is noteworthy that mutations within the hepato-
cyte nuclear factor (HNF)-1β gene, originally found asso-
ciated with MODY-type diabetes [82] and with diabetes
mellitus, renal dysfunction and genital malformations
[83], were suspected to account for an MRKH-like pheno-
type [83,84] (OMIM 158330 [25]). However, absence of
phenotype/genotype correlation in addition to non-
MRKH uterine malformations [84] is not consistent with
a straight relationship between MRKH syndrome and
HNF-1β gene defects. Finally, we investigated a patient
showing uterovaginal agenesis combined with unilateral
renal aplasia and MODY-type diabetes and did not find
any mutation in the HNF-1β gene (unpublished results).
The particular case of Wnt genes
Wnt genes encode secreted glycoproteins that regulate cell
and tissue growth and differentiation during embryogen-
esis [85]. Three members of the Wnt gene family, Wnt4,
Wnt5a and Wnt7a, are expressed at high levels in the
developing female genital tract, in the mouse model [86].
Homozygotic inactivation of each of these genes results,
in all cases, in severe Müllerian ducts defects, ranging fromJournal of Negative Results in BioMedicine 2006, 5:1 http://www.jnrbm.com/content/5/1/1
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DES exposure-like malformation [87] to total failure of
Müllerian duct formation amongst numerous lethal
defects at birth [88]. A loss-of-function mutation in the
Wnt4 gene was recently described in association with an
absence of Müllerian-derived structures, unilateral renal
agenesis, and clinical signs of androgen excess in an 18-
year-old woman [89]. The congenital malformations
observed in this patient suggested a MRKH-like pheno-
type although no skeletal anomaly was evidenced. How-
ever the complete absence of Müllerian structure seems to
be due to ectopic expression of AMH by masculinized
ovaries during fetal life, as explained by the authors. In
addition, ovarian masculinization is never observed in
well diagnosed MRKH syndrome and therefore the loss-
of-function mutation of Wnt4 is not a very likely the cause
of the syndrome. Sequencing of the Wnt4 gene in 19
MRKH patients [90] supports this idea. Wnt4 is a major
developmental gene required for normal kidney and
female gonad differentiation and its role takes place early
in embryogenesis, prior to Müllerian differentiation [88].
It may, in addition, play an important role in Müllerian
duct differentiation. If so, Müllerian duct-targeted disrup-
tion of the Wnt4 gene in the mouse may give an answer.
For instance, the role of Bmpr1 in Müllerian duct regres-
sion was proven using this tissue-specific targeting strat-
egy [91].
The involvement of Wnt5a and Wnt7a during female gen-
ital tract development has been demonstrated [92,93]: the
female genital tract malformations in Wnt5a and Wnt7a
mutant mice are similar to those described in HOXA11
and HOXA13 transgenic mice bearing homozygotic null
alleles [94,95]. Interestingly, uterine malformations
observed in these latter knocked-out mice strongly resem-
ble to those reported for animals exposed in utero to DES
and in which HOXA10, HOXA11 [96] as well as Wnt7a
gene expression is altered [87].
It therefore appears that some Wnt and HOX genes prod-
ucts co-operate to pattern female genital tract during
mouse embryogenesis as recently postulated [92]. Data
discussed above tend to show that Wnt4, Wnt5A and
Wnt7A genes are not good candidates for genes contribut-
ing to MRKH syndrome: however this generalization does
not apply to the HOX genes.
The HOX genes hypothesis
In 1999, JL Simpson [21] deplored the absence of molec-
ular progress "despite potentially attractive candidate genes" –
he also pointed out that "a great interest lies in developmen-
tal genes, like those in the HOX series". The point has been
made again recently [59,97]. Indeed there are clearly very
few genes known to be involved in the differentiation of
Müllerian duct as well as kidney and skeleton: these are
mainly the HOX genes which have been studied through
their pattern of segmentally based expression and by in
vivo  inactivation (knock-out) in the mouse model. It
emerges from these experiments that HOXA10 [98],
HOXA11 [94] and HOXA13 [95] seem to be required for
correct Müllerian duct differentiation. Furthermore, these
latter genes are also expressed in the developing kidney
[99] and patterning of the skeleton requires both
HOXA10 and HOXA11 [100].
In human, mutations within HOXA13 gene or deletion of
the HOXA gene cluster mainly affect uro-genital tract and
skeleton. Mutations in HOXA13 coding region cause
handfoot-genital syndrome (HFGS) which is character-
ized by hand malformations, hypospadias in males,
Müllerian duct fusion defects in females (ranging from
longitudinal vaginal septum to double uterus with double
cervix) and urinary tract malformations in both sexes
[101,102]. Surprisingly, deletion of the whole HOXA clus-
ter does not cause more uro-genital anomalies than single
mono-allelic HOXA13 mutations [103]. This suggests that
either mono-allelic dominant mutations within HOXA9,
-A10 or -A11 may account for the MRKH syndrome or this
can be due to other mechanisms such as mis-regulation of
HOXA genes, affecting either transcription rate or spatio-
temporal expression: the recent finding of a mutation
within the HOXA13 gene promoter [104] strengthens this
hypothesis.
Conclusion
Incidence of the MRKH syndrome/MURCS association
has probably been underevaluated mainly because it has,
until recently, been seen as a female-specific and sporadic
disorder. Isolated features of the triad of main malforma-
tions, including kidney agenesis and/or skeletal defects,
were consequently not investigated in all probands' rela-
tives, including males who can also be affected. This is
understandable given the incomplete degree of pene-
trance, variable expressivity and similarities of this syn-
drome with other genetic disorders.
Treatment which consists in creating a neovagina is gener-
ally offered to patients when they are ready to start sexual
activity. Moreover, everyday improvement of medical
technologies allows, in many countries, women to appeal
for in vitro fertilization and surrogate pregnancy to bypass
the absence of inner genital tract. The number of such
women will probably increase with time. This is why char-
acterization of the genetic events responsible for this syn-
drome is of major importance.
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